SPOTLIGHT -
Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer
This nonblinded, multicenter, randomized phase III study compares the median time to progression (primary endpoint), response rate, and quality of life, safety, and survival of
